Advertisement

Current Oncology Reports

, 21:2 | Cite as

Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development

  • Mayanne M. T. Zhu
  • Amanda R. Dancsok
  • Torsten O. NielsenEmail author
Evolving Therapies (RM Bukowski, Section Editor)
  • 177 Downloads
Part of the following topical collections:
  1. Topical Collection on Evolving Therapies

Abstract

Purpose of Review

This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.

Recent Findings

IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target. Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation. Combinations with anti-PD-1/PD-L1 antibodies are already showing promise, and related strategies are under active evaluation.

Summary

While further research is needed to elucidate the precise role of IDO-1 in tumor development, its mechanisms of action appear sufficiently distinct from other immunotherapy targets to warrant inclusion in combination immunotherapy regimens, an approach where multiple clinical trials are currently underway.

Keywords

Immune checkpoint blockade Immuno-oncology Combination therapy Epacadostat Indoximod BMS-986205 

Notes

Funding Information

This work was supported by grants from the Canadian Cancer Society and the Liddy Shriver Sarcoma Initiative.

Compliance with Ethical Standards

Conflict of Interest

Mayanne M.T. Zhu declares that she has no conflict of interest.

Amanda R. Dancsok declares that she has no conflict of interest.

Torsten O. Nielsen has received research funding through a grant from Novartis; has received compensation as well as non-financial support from NanoString Technologies, Inc., for service as a consultant; has received compensation from Epizyme for service as a consultant; and has a patent (PAM50 breast cancer subtype and prognostic signature) issued, licensed to NanoString Technologies, and receives royalties, although this is not directly related to the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefGoogle Scholar
  2. 2.
    Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:1–18.CrossRefGoogle Scholar
  3. 3.
    Khalil DN, Smith EL, Brentjens RJ, Wolchok JD, Sloan M, Cancer K. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–90.CrossRefGoogle Scholar
  4. 4.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefGoogle Scholar
  5. 5.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.Google Scholar
  6. 6.
    Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–47.Google Scholar
  7. 7.
    Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefGoogle Scholar
  8. 8.
    Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.Google Scholar
  9. 9.
    Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive ‘cold’ tumors ‘hot’. Trends Cancer. 2018;4:38–58.CrossRefGoogle Scholar
  10. 10.
    Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.CrossRefGoogle Scholar
  11. 11.
    Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:1–14.CrossRefGoogle Scholar
  12. 12.
    • Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 2015;13:412–24. This study demonstrates that the anti-tumor effect of indoximod in murine melanome model is related to reduced MDSC activity. Google Scholar
  13. 13.
    Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem. 1988;263:2041–8.PubMedGoogle Scholar
  14. 14.
    Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci U S A. 1988;85:1242–6.CrossRefGoogle Scholar
  15. 15.
    Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Antonia SJ, et al. Potential regulatory function of human dendritic cells expressing indoleamine. Science. 2002;297(80):1867–71.CrossRefGoogle Scholar
  16. 16.
    Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280–90.Google Scholar
  17. 17.
    Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–42.CrossRefGoogle Scholar
  18. 18.
    Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. mTOR differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30:832–44.Google Scholar
  19. 19.
    Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203.CrossRefGoogle Scholar
  20. 20.
    Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71.Google Scholar
  21. 21.
    Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185:3190–8.CrossRefGoogle Scholar
  22. 22.
    Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, Wu M, and Wainwright DA. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018; 15(5): 447–457.  https://doi.org/10.1038/cmi.2017.143.
  23. 23.
    Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77:6795–811.CrossRefGoogle Scholar
  24. 24.
    •• Theate I, van Baren N, Pilotte L, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015;3:161–72. This is the first study to thoroughly characterize the expression of IDO-1 protein in 15 types of solid tumor cancers in human, and show that IDO-1 expression is distributed in different cell types depending on the cancer type. CrossRefGoogle Scholar
  25. 25.
    Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, De Plaen E, et al. Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol Res. 2017;5:695–710.CrossRefGoogle Scholar
  26. 26.
    Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106:2375–81.CrossRefGoogle Scholar
  27. 27.
    Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y. Up-regulation of PD-L1, IDO, and T regs in the melanoma tumor microenvironment is driven by CD8 + T Cells. Sci Transl Med. 2013;5:200ra116.CrossRefGoogle Scholar
  28. 28.
    Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011;12:870–8.Google Scholar
  29. 29.
    Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.Google Scholar
  30. 30.
    Folgiero V, Goffredo BM, Filippini P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 2014;5:2052–64.CrossRefGoogle Scholar
  31. 31.
    Moretti S, Menicali E, Voce P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab. 2014;99:832–40.CrossRefGoogle Scholar
  32. 32.
    Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, et al. Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1. Am J Surg Pathol. 2018;00:1–8.Google Scholar
  33. 33.
    Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, et al. Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer. Clin Cancer Res. 2017;23:370–8.Google Scholar
  34. 34.
    Dill EA, Dillon PM, Bullock TN, Mills AM. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol. 2018; 31(10):1513-1522.  https://doi.org/10.1038/s41379-018-0061-3.
  35. 35.
    Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:1–9.CrossRefGoogle Scholar
  36. 36.
    Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–97.CrossRefGoogle Scholar
  37. 37.
    Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC, Ring KL. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 2018;31(8):1282-1290.  https://doi.org/10.1038/s41379-018-0039-1.
  38. 38.
    Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med. 2015;10:1947–52.CrossRefGoogle Scholar
  39. 39.
    Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016;19:42–52.Google Scholar
  40. 40.
    Meireson A, Chevolet I, Hulstaert E, Ferdinande L, Ost P, Geboes K, et al. Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget. 2018;9:25216–24.Google Scholar
  41. 41.
    Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596–9.CrossRefGoogle Scholar
  42. 42.
    • Lemos H, Mohamed E, Huang L, Ou R, Pacholczyk G, Arbab AS, et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 2016;76:2076–81. This study shows that tumor antigenicity is associated with IDO activation through STING, in which tumors with low antigenticy induces a tolerogenic response and tumors with high antigenicity incites inflammatory response. Google Scholar
  43. 43.
    Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–402.CrossRefGoogle Scholar
  44. 44.
    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.Google Scholar
  45. 45.
    Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110:2560–8.Google Scholar
  46. 46.
    Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103.CrossRefGoogle Scholar
  47. 47.
    Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5:585–90.CrossRefGoogle Scholar
  48. 48.
    Wang W, Huang L, Jin J-Y, et al. IDO immune status after chemoradiation may predict survival in lung cancer patients. Cancer Res. 2017;78:809–16.CrossRefGoogle Scholar
  49. 49.
    Ferns DM, Kema IP, Buist MR, Nijman HW, Gemma G, Jordanova ES. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology. 2015;4:1–7.CrossRefGoogle Scholar
  50. 50.
    Nam SJ, Kim S, Kwon D, et al. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2018;7:1–12.CrossRefGoogle Scholar
  51. 51.
    Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y, Lesniak MS. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014; 20(20): 5290–5301.  https://doi.org/10.1158/1078-0432.CCR-14-0514.
  52. 52.
    Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, et al. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immunol. 2017;62:24–9.Google Scholar
  53. 53.
    Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, et al. IDO1 metabolites activate β-catenin Signaling. Gastroenterology. 2013;145:416–25.Google Scholar
  54. 54.
    Liu X, Zhou W, Zhang X, Ding Y, Du Q, Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells. Int J Cancer. 2018;143:1516–29.  https://doi.org/10.1002/ijc.31417.CrossRefPubMedGoogle Scholar
  55. 55.
    • Liu Y, Liang X, Yin X, et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nat Commun. 2017;8:1–15. This study demonstrates a novel IDO-dependent pathway that induces tumor dormancy through IFN γ, which can be reversed by administration of 1-MT. CrossRefGoogle Scholar
  56. 56.
    Ball HJ, Sanchez-Perez A, Weiser S, Austin CJD, Astelbauer F, Miu J, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203–13.Google Scholar
  57. 57.
    Hjortsø MD, Larsen SK, Kongsted P, et al. Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology. 2015;4:968480.CrossRefGoogle Scholar
  58. 58.
    Lee YK, Lee HB, Shin DM, Kang MJ, Yi EC, Noh S, et al. Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. Exp Mol Med. 2014;46:e121–11.Google Scholar
  59. 59.
    Liu Y, Zhang Y, Zheng X, Zhang X, Wang H, Li Q,Yuan K, Zhou N, Yu Y, Song N, Fu J, Min W. Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth. Oncotarget. 2016; 7(22): 32329–32340.  https://doi.org/10.18632/oncotarget.8617.
  60. 60.
    Cheong JE, Sun L. Targeting the IDO1/TDO2–KYN–AhR pathway for cancer immunotherapy – challenges and opportunities. Trends Pharmacol Sci. 2018;39:307–25.CrossRefGoogle Scholar
  61. 61.
    Chen J, Li C, Kuo C, Tsai KK, Hou M, Hung W. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2 , 3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014;16:410.CrossRefGoogle Scholar
  62. 62.
    Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. 2016;7:37762–72.Google Scholar
  63. 63.
    • Soliman HH, Minton SE, Han HS, et al. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016;7:22928–38. This is the first published clinical study that uses indoximod to treat patients with advanced malignancies. Hypophysitis in three cases was the only adverse event attributed to navoximod. The best response was stable disease in 5 out of 48 patients. PubMedPubMedCentralGoogle Scholar
  64. 64.
    • Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23:3269–76. This is the first published clinical study that uses epacadostat to treat patients with advanced solid malignancies. Two dose-limiting toxicities, a grade 3 radiation pneumonitis, and grade 3 fatigue occured at at dose 300 mg BID and 400 mg BID, respectively. Stable disease was detected in 18 patients (34.6%), but no objective response was observed. CrossRefGoogle Scholar
  65. 65.
    • Nayak-Kapoor A, Hao Z, Sadek R, et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer. 2018;6:61. This is the first published clinical study that uses navoximod to treat patients with recurrent advanced solid tumors. Two patients (9%) reported grade ≥ 3 adverse effects related to navoximod, which was a grade 4 lower gastrointestinal hemorrhage and a grade 3 diverticulitis. Stable disease was detected in 8 patients (36%), but there was no objective response. CrossRefGoogle Scholar
  66. 66.
    Komrokji RS, Wei S, Mailloux AW, et al. A phase II study to determine the safety and efficacy of the Oral inhibitor of Indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes. Blood. 2014;124:4653 LP-4653.Google Scholar
  67. 67.
    Kristeleit R, Davidenko I, Shirinkin V, el-Khouly F, Bondarenko I, Goodheart MJ, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol. 2017;146:484–90.Google Scholar
  68. 68.
    Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Krüse V, Schreuer M, et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol. 2014;171:987–95.Google Scholar
  69. 69.
    Denkert C, Von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983–91.CrossRefGoogle Scholar
  70. 70.
    Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial. JAMA Oncol. 2018;4:93–7.Google Scholar
  71. 71.
    Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, et al. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. 2018;67:1305–15.Google Scholar
  72. 72.
    Burris HA, Gordon MS, Hellmann MD, LoRusso P, Emens LA, Hodi FS, et al. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. J Clin Oncol. 2017;35:105.  https://doi.org/10.1200/JCO.2017.35.15_suppl.105.
  73. 73.
    Tabernero J, Luke JJ, Joshua AM, Varga AI, Moreno V, Desai J, et al. BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC). J Clin Oncol. 2018;36:4512.  https://doi.org/10.1200/JCO.2018.36.15_suppl.4512.
  74. 74.
    Zakharia Y, Drabick J, Khleif S, Munn D, Link C, Vahanian N, et al. Abstract CT087: phase II trial of the indoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus immune checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. Cancer Res. 2016;76:CT087 LP-CT087.Google Scholar
  75. 75.
    Naing A, Powderly JD, Falchook G, et al. Abstract CT177: epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study. Cancer Res. 2018;78:CT177 LP-CT177.CrossRefGoogle Scholar
  76. 76.
    Smith DC, Gajewski T, Hamid O, Wasser JS, Olszanski AJ, Patel SP, et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO-202/KEYNOTE-037. J Clin Oncol. 2017;35:4503.  https://doi.org/10.1200/JCO.2017.35.15_suppl.4503.CrossRefGoogle Scholar
  77. 77.
    Lara P, Bauer TM, Hamid O, Smith DC, Gajewski T, Gangadhar TC, et al. Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I/II results from ECHO-202/KEYNOTE-037. J Clin Oncol. 2017;35:4515.  https://doi.org/10.1200/JCO.2017.35.15_suppl.4515.
  78. 78.
    Hamid O, Gajewski TF, Frankel AE, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037. Ann Oncol. 2017;28:mdx377.001.Google Scholar
  79. 79.
    Gangadhar TC, Schneider BJ, Bauer TM, Wasser JS, Spira AI, Patel SP, et al. Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I/II results of ECHO-202/KEYNOTE-037. J Clin Oncol. 2017;35:9014.  https://doi.org/10.1200/JCO.2017.35.15_suppl.9014.
  80. 80.
    Spira AI, Hamid O, Bauer TM, Borges VF, Wasser JS, Smith DC, et al. Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: phase I/II ECHO-202 study. J Clin Oncol. 2017;35:1103.  https://doi.org/10.1200/JCO.2017.35.15_suppl.1103.
  81. 81.
    Daud A, Saleh MN, Hu J, Bleeker JS, Riese MJ, Meier R, et al. Epacadostat plus nivolumab for advanced melanoma: updated phase 2 results of the ECHO-204 study. J Clin Oncol. 2018;36:9511.  https://doi.org/10.1200/JCO.2018.36.15_suppl.9511.
  82. 82.
    Perez RP, Riese MJ, Lewis KD, Saleh MN, Daud A, Berlin J, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204. J Clin Oncol. 2017;35:3003.  https://doi.org/10.1200/JCO.2017.35.15_suppl.3003.
  83. 83.
    Long GV, Dummer R, Hamid O, Gajewski T, Caglevic C, Dalle S, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol. 2018;36:108.  https://doi.org/10.1200/JCO.2018.36.15_suppl.108.
  84. 84.
    Gibney GT, Hamid O, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol. 2014;32:3010.  https://doi.org/10.1200/jco.2014.32.15_suppl.3010.
  85. 85.
    Gibney GT, Hamid O, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol. 2014;32:3010.  https://doi.org/10.1200/jco.2014.32.15_suppl.3010.CrossRefGoogle Scholar
  86. 86.
    Yap TA, Sahebjam S, Hong DS, Chiu VK, Yilmaz E, Efuni S, et al. First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors. J Clin Oncol. 2018;36:3040.  https://doi.org/10.1200/JCO.2018.36.15_suppl.3040.
  87. 87.
    Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, et al. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018;9:10110–7.Google Scholar
  88. 88.
    Slingluff CL, Fling S, Mauldin IS, Ernstoff MS, Hanks BA, Delman KA, et al. Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. J Clin Oncol. 2018;36:3033.  https://doi.org/10.1200/JCO.2018.36.15_suppl.3033.
  89. 89.
    Dorigo O, Tanyi JL, Strauss J, Oza AM, Pejovic T, Ghatage P, et al. Clinical data from the DeCidE1 trial: assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. J Clin Oncol. 2018;36:5510.  https://doi.org/10.1200/JCO.2018.36.15_suppl.5510.
  90. 90.
    Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. Oncoimmunology. 2013;2:e23428.CrossRefGoogle Scholar
  91. 91.
    Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014;2:21.Google Scholar
  92. 92.
    Monjazeb AM, Kent MS, Grossenbacher SK, Mall C, Zamora AE, Mirsoian A, et al. Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies. Clin Cancer Res. 2016;22:4328–40.Google Scholar
  93. 93.
    Jackson E, Dees EC, Kauh JS, Harvey RD, Neuger A, Lush R, Antonia SJ, Minton SE, Ismail-Khan R, Han HS, Vahanian NN, Ramsey WJ, Link CJ, Streicher H, Sullivan D, and Soliman HH. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. J Clin Oncol 2013 31:15_suppl, 3026-3026.Google Scholar
  94. 94.
    Zakharia Y, Munn D, Link C, Vahanian N, Kennedy E. Actr-53. Interim analysis of phase 1B/2 combination study of the Ido pathway inhibitor Indoximod with Temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors. Neuro-Oncology. 2016;18:vi13–4.CrossRefGoogle Scholar
  95. 95.
    Johnson TS, Aguilera D, Al-Basheer A, et al. Abstract CT004: front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy. Cancer Res. 2018;78:CT004 LP.CrossRefGoogle Scholar
  96. 96.
    Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, O'Rourke MA, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. J Clin Oncol. 2018;36:4015.  https://doi.org/10.1200/JCO.2018.36.15_suppl.4015.
  97. 97.
    Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014;20:221–32.Google Scholar
  98. 98.
    Kjeldsen JW, Iversen TZ, Noerregaard LE, Mellemgaard A, Andersen MH, Svane I-M. Long-term follow-up results of stage III-IV non-small cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 dioxygenase (IDO) in a phase I study. Ann Oncol. 2017;28:mdx380.028.Google Scholar
  99. 99.
    Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy. 2016;18:1043–55.CrossRefGoogle Scholar
  100. 100.
    Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2018;36:179–90.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mayanne M. T. Zhu
    • 1
  • Amanda R. Dancsok
    • 1
  • Torsten O. Nielsen
    • 1
    Email author
  1. 1.Genetic Pathology Evaluation Centre, Department of Pathology & Laboratory MedicineUniversity of British ColumbiaVancouverCanada

Personalised recommendations